Multi-indication Pembrolizumab Cost-effectiveness

Description

This study aimed to perform a cost-effectiveness analysis evaluating 31 combinations of pembrolizumab use across five solid tumor indications—non-small cell lung cancer (NSCLC), Esophagus, Breast, Melanoma, and Cervical cancer—from the perspective of the Brazilian public health system. The model is uploaded with all data for analysis

Steps to reproduce

Download treeage pro and run the model.

Categories

Licence